FIELD: pharmaceuticals.
SUBSTANCE: pharmaceutical compositions and methods for using the compounds for the inhibition of MMP-12 and the treatment of diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, non-alcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis are also described.
EFFECT: compounds based on hydantoin, useful as inhibitors of matrix metalloproteinases (MMPs), in particular macrophage elastase (MMP-12).
18 cl, 2 dwg, 9 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2797558C2 |
| 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND VARIANTS OF THEIR USE | 2018 |
|
RU2795850C2 |
| SPIROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND USE | 2018 |
|
RU2781639C2 |
| INTEGRATED STRESS PATHWAY PRODRUG MODULATORS | 2019 |
|
RU2824500C2 |
| N1-(4-(5-(CYCLOPROPYLMETHYL)-1-METHYL-1H-PYRAZOLE-4-YL)PYRIDINE-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF CK1 AND/OR IRAK1 FOR THE TREATMENT OF CANCER | 2018 |
|
RU2761457C2 |
| PYRAZOLE-BASED MAGL INHIBITORS | 2018 |
|
RU2789157C2 |
| ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2020 |
|
RU2824528C2 |
| ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | 2019 |
|
RU2797622C2 |
| NOVEL PYRAZOLE DERIVATIVES | 2022 |
|
RU2816835C1 |
| DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND THEIR USE | 2019 |
|
RU2787766C2 |
